Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
VolitionRx management to meet with Oppenheimer » 04:55
02/28/20
02/28
04:55
02/28/20
04:55
VNRX

VolitionRx

$3.36 /

-0.85 (-20.19%)

Meeting to be held in New…

Meeting to be held in New York on February 28 hosted by Oppenheimer.

ShowHide Related Items >><<
Conference/Events
VolitionRx management to meet with Oppenheimer » 09:44
02/25/20
02/25
09:44
02/25/20
09:44
VNRX

VolitionRx

$4.57 /

+ (+0.00%)

Meeting to be held in New…

Meeting to be held in New York on February 28 hosted by Oppenheimer.

ShowHide Related Items >><<
Conference/Events
VolitionRx management to meet with Oppenheimer » 04:55
02/24/20
02/24
04:55
02/24/20
04:55
VNRX

VolitionRx

$4.58 /

-0.41 (-8.22%)

Meeting to be held in…

Meeting to be held in Boston on February 24 hosted by Oppenheimer.

ShowHide Related Items >><<
Hot Stocks
VolitionRx reports cash and cash equivalents at year-end of $17M » 16:45
02/20/20
02/20
16:45
02/20/20
16:45
VNRX

VolitionRx

$4.99 /

+0.23 (+4.83%)

Cash and cash equivalents…

Cash and cash equivalents at end of 2018 were $12.4M. Expects to achieve the following milestones during 2020: release a range of clinical data with new optimised bead-based assays in colorectal, lung and other cancers; advance previously announced large-scale colorectal and lung cancer trials in Europe, Asia and the U.S.; advance the development of Nu.Q Capture by determining the level of discrimination of tumor associated nucleosomes using mass spectrometry and/or sequencing; announce patient data demonstrating the utility of Volition's epigenetic toolbox; complete pre-analytical and clinical studies for Nu.Q(TM) Vet with the aim of launching first product in 2020; publish several abstracts and peer reviewed articles with clinical results as well as showing the robustness and utility of the Nu.Q platform.

ShowHide Related Items >><<
Conference/Events
VolitionRx management to meet with Oppenheimer » 09:15
02/20/20
02/20
09:15
02/20/20
09:15
VNRX

VolitionRx

$4.76 /

-0.1 (-2.06%)

Meeting to be held in…

Meeting to be held in Boston on February 24 hosted by Oppenheimer.

ShowHide Related Items >><<
Syndicate
VolitionRx files to sell 9.81M shares of common stock for holders  17:28
02/07/20
02/07
17:28
02/07/20
17:28
VNRX

VolitionRx

$4.35 /

-0.28 (-6.05%)

 
ShowHide Related Items >><<
Options
Six new option listings and two option delistings on January 2nd » 08:30
01/02/20
01/02
08:30
01/02/20
08:30
ALEC

Alector

$17.22 /

+0.34 (+2.01%)

, BRMK

Broadmark Realty Capital

$12.70 /

-0.02 (-0.16%)

, COLD

Americold Realty Trust

$35.09 /

+0.49 (+1.42%)

, DHC

Diversified Healthcare Trust

$8.43 /

+0.32 (+3.95%)

, VNRX

VolitionRx

$4.72 /

+0.11 (+2.39%)

, CECO

Symbol changed to PRDO

$18.39 /

+0.08 (+0.44%)

, SNH

Senior Housing

$8.43 /

+0.32 (+3.95%)

New option listings for…

New option listings for January 2nd include Alector Inc (ALEC), Broadmark Realty Capital Inc (BRMK), Americold Realty Trust (COLD), Diversified Healthcare Trust (DHC), Perdoceo Education Corporation (PRDO), and VolitionRX (VNRX). Option delistings effective January 2nd include Career Education Corp (CECO) and Senior Housing Properties Trust (SNH).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
Hot Stocks
VolitionRx to acquire Octamer for approximately $725,000 » 08:31
12/16/19
12/16
08:31
12/16/19
08:31
VNRX

VolitionRx

$4.46 /

-0.14 (-3.04%)

VolitionRx announced an…

VolitionRx announced an agreement by its subsidiary Belgian Volition SPRL to acquire an epigenetic reagent company, Octamer GmbH, for approximately $725,000 consisting of cash and shares of restricted common stock of Volition. The closing of the acquisition is subject to customary conditions and is expected to occur in January 2020. This strategic acquisition helps secure the supply of one of the key components of Volition's Nu.QTM tests, the recombinant nucleosome used as the calibrant.

Hot Stocks
VolitionRx announces proof of concept study on Lymphoma and Leukemia » 08:33
12/03/19
12/03
08:33
12/03/19
08:33
VNRX

VolitionRx

$5.24 /

-0.14 (-2.60%)

VolitionRx announced…

VolitionRx announced results from its latest proof of concept study. A single pre-clinical Nu.Q assay utilizing a basic microtiter plate platform detected 80% of newly diagnosed Non-Hodgkins Lymphoma and Leukemia cases at 95% specificity among healthy subjects. The Area Under the Curve, or AUC, for this single assay was 91%. A number of other assays in development also demonstrated promising individual assay results with AUCs ranging from 79% to 91%.

ShowHide Related Items >><<
Hot Stocks
VolitionRx reports cash and cash equivalents as of September 30 totaled $19.7M » 16:19
11/12/19
11/12
16:19
11/12/19
16:19
VNRX

VolitionRx

$5.22 /

-0.23 (-4.22%)

Cash and cash equivalents…

Cash and cash equivalents as of September 30 totaled $19.7M compared to $13.4M as of the end of 2018. The company said "During the Q3 we further strengthened our balance sheet with an existing investor exercising $4.8M in aggregate amount of outstanding warrants to purchase shares of our common stock making a total of $16.5M in warrants exercised during the first three quarters of 2019 and ended the quarter with cash and cash equivalents of $19.7M. During the Q3 we were awarded a further $1.4M in non-dilutive grant-funding from the Walloon Region and, subsequent to quarter end, an additional $500,000 unsecured loan from SOFINEX was approved. We also recorded our first revenues this quarter from sales of our Research Use Only kits and the provision of services."

ShowHide Related Items >><<

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.